AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.6 |
Market Cap | 159.63M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.71 |
PE Ratio (ttm) | -0.95 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.63 |
Volume | 701,674 |
Avg. Volume (20D) | 1,314,491 |
Open | 1.82 |
Previous Close | 1.79 |
Day's Range | 1.61 - 1.82 |
52-Week Range | 1.61 - 7.78 |
Beta | undefined |
About ALEC
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, incl...
Analyst Forecast
According to 5 analyst ratings, the average rating for ALEC stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 145.40% from the latest price.
Next Earnings Release
Analysts project revenue of $16.80M, reflecting a 10.60% YoY growth and earnings per share of -0.61, making a 24.49% increase YoY.